Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Cancer
CSPC Pharmaceutical’s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...
Hanx Bio Files for Hong Kong IPO with ICBC International as Sole Sponsor
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing...
Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship
China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...
InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248
Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical...
Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Co., Ltd’s rocbrutinib is currently under New Drug Application (NDA) review at...
Bayer’s Sevabertinib Receives FDA Priority Review for HER2-mutant NSCLC
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its investigational oral small-molecule tyrosine kinase...
JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
Sino Medical Sciences Technology’s AUCURA Flow-Diverting Stent Approved by NMPA
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its holding subsidiary Neurovita has...
Changchun Pharma Wins FDA Approval for GenSci128 in TP53 Y220C Solid Tumors
China-based Changchun High & New Technology Industries (Group) Inc., (SHE:000661) announced that its subsidiary Changchun...
Guided Therapeutics Receives Payment from Shandong Yaohua for LuViva Commercialization
US-based Guided Therapeutics, Inc. (OTCMKTS: GTHP), a developer of rapid, painless testing platforms based on...
AstraZeneca’s Imfinzi Gets Positive Opinion for Bladder Cancer Perioperative Treatment
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that the European Medicines Agency’s (EMA) Committee...
EMA Recommends Tevimbra for Nasopharyngeal Cancer First-line Treatment
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...
CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the Center for Drug Evaluation...
EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager
Shanghai-based biotech EpimAb Biotherapeutics announced a global licensing agreement with US-headquartered Juri Biosciences, Inc., a...
Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study
Sino-US biotech Phanes Therapeutics Inc. announced the first patient dosing in a clinical study for...
Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC
Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech...
Kexing Pharma’s GB18 Receives NMPA Approval for Cancer Cachexia Trial
China-based Kexing Pharmaceutical (SHA: 688136) announced that it has received approval from the National Medical...